Skip to main content
. Author manuscript; available in PMC: 2023 Oct 18.
Published in final edited form as: J Am Coll Cardiol. 2022 Oct 18;80(16):1516–1525. doi: 10.1016/j.jacc.2022.08.735

Figure 2. Intensive SBP lowering effects on incident LVH and malignant LVH.

Figure 2.

Odds ratios with 95% confidence intervals obtained from logistic regression models. Panel A displays proportion without LVH at baseline who developed LVH during follow-up stratified by randomized treatment assignment and baseline cardiac biomarker levels. Biomarker+ indicates hs-cTnT ≥14 ng/L or NT-proBNP ≥125 pg/mL. Panel B displays proportion without malignant LVH at baseline who developed malignant LVH during follow-up stratified by randomized treatment assignment. Abbreviations: hs-cTnT, high-sensitivity cardiac troponin T; LVH, left ventricular hypertrophy; NT-proBNP, N-terminal pro-B-type natriuretic peptide; OR, odds ratio; SBP, systolic blood pressure; SPRINT, Systolic Blood Pressure Intervention Trial.